ArticleEClinicalMedicine2025

Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial.

Thomas M File et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.